The following is a summary of the Sensus Healthcare, Inc. (SRTS) Q4 2023 Earnings Call Transcript:

Financial Performance:

• Sensus Healthcare saw a decline in Q4 revenues for 2023, reporting $12.6 million compared to $13.1 million in the same period last year.

• The company shipped a total of 66 units in 2023, reflecting an improvement in sales.

• Despite the decline, net income in Q4 2023 was $4.2 million, higher than Q4 2022's net income of $2.8 million.

• Full year net income for 2023 was reported at $0.5 million, lower than the previous year's $24.2 million.

• Sensus ended 2023 with cash and equivalents worth $23.1 million, a decrease from $25.5 million at the end of 2022.

Business Progress:

• The company introduced a new recurring revenue model and improved their technology through high-resolution ultrasound and a new infusion product application.

• In line with its goal of opening 2-3 new territories per year, Sensus expanded into Ireland, Guatemala, and Turkey in 2023.

• Sensus collaborated with CureRays, which plans to treat patients using Sensus's technology.

• The company plans to expand its footprint in Latin America, Europe, and Asia.

• Sensus has added a new service to its recurring revenue model, offering operational support to certain practices.

• The development of a drug delivery system for the aesthetic market has been completed, and an application for its approval has been filed with the FDA.

More details: Sensus Healthcare IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.